The extraordinary spectrum of diseases
        caused by Aspergillus


           David W. Denning
        Wythenshawe Hospital
       University of Manchester
The genus Aspergillus - importance to humanity
 on the negative side:


   cause invasive and allergic disease
   in humans and other animals:
          A. fumigatus




   cause plant and food spoilage and
   produce mycotoxins:
           A. flavus and A. parasiticus



                                          www.aspergillus.man.ac.uk
The genus Aspergillus - importance to humanity

  on the positive side:

     composting

     well-established model organism in cell biology and genetics:
            A. nidulans

     food production:
            enzymes and organic acids: A. niger
            East Asian foods: A. oryzae and A. sojae

     pharmaceuticals:
           echinocandins: A. nidulans and A. sydowi
           lovastatin: A. terreus
           fumagillin: A. fumigatus

                                          www.aspergillus.man.ac.uk
Aspergillus Life-cycle




Spores inhaled            Germination




Mass of hyphae          Hyphal elongation
(plateau phase)          and branching


                            www.aspergillus.man.ac.uk
The genus Aspergillus – ~180 species,
38 have caused disease (able to grow at 37C)
Common in the environment




                                                   Aspergillus
      A. nidulans – may be amphotericin B resistant fumigatus
                                                  conidial head
    A. niger A. flavus -sometimes to AmB of azole resistance
                  A. fumigatus low frequency
           A. terreus – resistant amphotericin B resistant

                                           www.aspergillus.man.ac.uk
CLASSIFICATION OF ASPERGILLOSIS
                    Invasive aspergillosis
                    • Acute (<1 month course)
Airways/nasal       • Subacute/chronic necrotising (1-3 months)
exposure to
airborne            Chronic aspergillosis (>3 months)
Aspergillus
                    • Chronic cavitary pulmonary
                    • Aspergilloma of lung
                    • Chronic fibrosing pulmonary
                    • Chronic invasive sinusitis
Persistence         • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or      Allergic
nose/sinuses        • Allergic bronchopulmonary (ABPA)
                    • Extrinsic allergic (broncho)alveolitis (EAA)
                    • Asthma with fungal sensitisation
                    • Allergic Aspergillus sinusitis (eosinophilic
                             fungal rhinosinusitis)
Immunosuppression and infection

• Inhalation of aspergillus spores is a common
  daily occurrence. A healthy immune system
  would normally remove the spores and no
  symptoms or infection would occur.

• In individuals whose immune system may be
  suppressed either because of illness eg AIDS,
  cancer patients or drugs, spores may germinate
  and resulting tissue or systemic aspergillus
  invasion can result.

• Individuals with allergies such as asthma, can
  also be vulnerable to aspergillus disease.
Interaction of Aspergillus with the host
                               A unique microbial-host interaction




                                                                                              Frequency of aspergillosis
Frequency of aspergillosis




                                   Acute IA
                                                                  ABPA
                                                                  Allergic sinusitis
                                         Subacute IA
                                                   Tracheobronchitis
                                                   Aspergilloma
                                                   Chronic cavitary
                                                   Chronic fibrosing




                              Immune dysfunction        Normal     Immune hyperactivity
                                                       immune
                                                       function
                                                        .         www.aspergillus.man.ac.uk
Changing incidence of fatal invasive
mycoses in non-HIV patients in USA

                                  0.8
      Rate per 100,000 population
          0.2     0.4     0.6




                                                                 Candidiasis
                                                                 Aspergillosis
  0.0




                                        1981   1986       1991         1996



                                                  McNeil et al, Clin Infect Dis 2001;33:641
Invasive pulmonary aspergillosis



       IPA                                         Normal lung




IPA occurs in ~7%
of acute leukaemia
 patients, 10-15%
  allogeneic BMT
      patients




                                   www.aspergillus.man.ac.uk
Unequivocal ‘Halo sign’ surrounding a nodule




Halo sign

                   Herbrecht, Denning et al, NEJM 2002;347:408-15.
Recent examples of the frequency of invasive
                aspergillosis
   Underlying condition      Incidence      Reference/year
Acute myeloid leukaemia         8%       Cornet, 2002
Acute lymphatic leukaemia      6.3%      Cornet, 2002
Allogeneic HSCT               11-15%     Grow, 2002;
                                         Marr, 2002

Lung transplantation         6.2-12.8%   Minari, 2002;
                                         Singh,2003

Heart-lung transplantation     11%       Duchini, 2002
Small bowel tranplantation     11%       Duchini, 2002
AIDS                           2.9%      Libanore, 2002
Bleeding as an aspect of disseminated
        invasive aspergillosis



                          Fumagillin is anti-angiogenic

                          A haemolysin described from
                          Aspergillus fumigatus

                          Other factors that
                          contribute to thrombosis or a
                          coagulopathy?




                 Gillies & Campbell, www.aspergillus.man.ac.uk
How does Aspergillus fumigatus cause
     thrombosis (clotting of vessels) and
               also bleeding?



Interaction of
  conidia and
endothelial cell                                                     Internalisation of
  projections                                                       conidia (and hyphae)
                                                                    by endothelial cells
                                                                    with injury apparent
                                                                         at 4 hours




             Filler et al, Blood 2004;103:2134; Paris et al, Infect Immun 1997;65:1510.
Cerebral aspergillosis (abscess) in
  chronic lymphocytic leukaemia

                        Dissemination via
                      the blood stream to
                       the brain occurs in
                        ~5% of cases of
                            invasive
                       aspergillosis, and in
                       ~40% of allogeneic
                      bone marrow (HSCT)
                           recipients




                          www.aspergillus.man.ac.uk
Early diagnosis of invasive aspergillosis
              is important

Treatment started            <10d >11d
Mortality                     40% 90%




                    Von Eiff et al, Respiration 1995;62:241-7.
Sputum Cultures for Fungus

Bacteriological media inferior to
    fungal media – 32% higher
      yield on fungal media




                                A four day A. fumigatus culture on malt
                                extract agar (above). Light microscopy
                               pictures are taken at 1000x, stained with
                                       lacto-phenol cotton blue.
Aspergillus Antigen Test

• Diagnosis or surveillance?
• Only blood, or BAL, CSF etc
• Best OD cut-off - 0.7
• False positives in kids / antibiotics
• False negative with antifungal
       prophylaxis
• Not as useful for non-hematology
• Not useful if pre-existing antibody




 Herbrecht et al, J Clin Microbiol 2002;20:1898-906; and others
Outcome from invasive aspergillosis –
       amphotericin B therapy
                    Survival Functions by Site of Infection
1.0

 .9


 .8
                                                                  Sinusitis (n =17)
 .7


 .6
                                                             Multi-site (n =11)

 .5

                                                      Aspe rgilloma (n =10)
 .4


 .3


 .2                                              Pu lmonary (n =83)


 .1
                                 CNS o r Dissemin ated (n =35)
0.0
      0   30   60     90   120      150    180      210    240        270     300   330   360


                                          Days


                                           Lin et al, Clin Infect Dis 2001;32:358
Sub-acute invasive aspergillosis in AIDS




                             www.aspergillus.man.ac.uk
Sub-acute invasive aspergillosis

•   Less immunocompromised patients
•   Slower progression of disease (> 1 month)
•   Cavitary or nodular pulmonary disease typical
•   Vascular invasion less common
•   Dissemination less common
•   Antigen testing less useful
•   Antibody testing may be helpful in diagnosis




                                   www.aspergillus.man.ac.uk
Chronic necrotizing aspergillosis
            (CNPA)
   Chronic necrotizing pulmonary aspergillosis
     (CNPA) is a subacute process usually found in
     patients with some degree of
     immunosuppression.
   Usually it is associated with underlying lung
     disease, alcoholism, or chronic corticosteroid
     therapy. Because it is uncommon, CNPA often
     remains unrecognized for weeks or months and
     causes a progressive cavitary pulmonary
     infiltrate.
Chronic necrotising pulmonary aspergillosis
                   Right upper lobe showing circular
                                                                 Right lobe shows huge cavity
                 shadow partly filled by a mass. PT MS
                                                                 containing some debris, with
                                  1996
                                                                 +ve aspergillus precipitins.Pt
                                                                           MS 1999




  Right upper lobe. Patient has           Same lobe shows expansion of
     diabetes and pulmonary              the shadow, still partially filled
mycobacterium avium- shows small            with a mass. Pt MS 1998
  cavitary lesion PT MS 1995.
                        Denning, Clin Microbiol Infect 2001;7(Suppl 2):25-31.
CLASSIFICATION OF ASPERGILLOSIS
                    Invasive aspergillosis
                    • Acute (<1 month course)
Airways/nasal       • Subacute/chronic necrotising (1-3 months)
exposure to
airborne            Chronic aspergillosis (>3 months)
Aspergillus
                    • Chronic cavitary pulmonary
                    • Aspergilloma of lung
                    • Chronic fibrosing pulmonary
                    • Chronic invasive sinusitis
Persistence         • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or      Allergic
nose/sinuses        • Allergic bronchopulmonary (ABPA)
                    • Extrinsic allergic (broncho)alveolitis (EAA)
                    • Asthma with fungal sensitisation
                    • Allergic Aspergillus sinusitis (eosinophilic
                             fungal rhinosinusitis)
Aspergillus and airways
Types of aspergillosis of the airways
• Colonisation (no disease – could be at risk)
• Obstructing Aspergillus tracheobronchitis /Mucus
     impaction (non-invasive)
• Aspergillus bronchitis/tracheobronchitis
(superficially invasive only)
• Ulcerative Aspergillus tracheobroncitis (locally
   invasive) (lung transplants – at anastomosis)
• Pseudomembranous Aspergillus tracheobronchitis
   (Extensive disease, locally invasive, associated with
   IPA and may disseminate)


                                         Langley, ATS 2004
Aspergillus tracheobronchitis


Autopsy drawing of a
‘normal’ 3 year old
who died over 10 days




                        Wheaton, Path Trans 1890; 41:34-37
Aspergillus tracheobronchitis

Review of 58 patients in literature for normal and
  immuno compromised patients - risk factors
                                         %
None (ie normal)                         25
Heart / Lung transplant                  18
Solid tumour                             15
BMT                                      13
Leukaemia                                13
HIV/AIDS                                  8
Other                                     8




                          Kemper et al, Clin Infect Dis 1993; 17: 344
Aspergilloma




                Fungus ball




               Patient RT
               December 2002
Chronic pulmonary aspergillosis – pre-existing
disease

All 18 patients had prior pulmonary
disease
     9 TB, 5 with atypical mycobacteria
     13 smokers or ex-smokers
     All 18 non-immunocompromised
     3 excess alcohol


              Denning DW et al, Clin Infect Dis 2003; 37:S265
Chronic pulmonary aspergillosis -
                   presentation

Weight loss                        16 / 18 (89%)
Cough                              15 / 18 (83%)
Shortness of breath                 9 / 18 (50%)
Haemoptysis                         9 / 18 (50%)
Fatigue / malaise                   5 / 18 (28%)
Chest pain                          3 / 18 (17%)
Sputum production ++                3 / 18 (17%)
Fever                               2 / 18 (11%)




                       Denning DW et al, Clin Infect Dis 2003; 37:S265
Chronic pulmonary aspergillosis -
                 serology
All 18 patients had positive Aspergillus precipitins
    (1+ - 4+)

All 18 patients had elevated inflammatory
    markers, CRP, PV and / or ESR

14 of 18 (78%) had elevated total IgE (>20), 13
   >200 and 7 >400

9 of 14 (67%) had Aspergillus specific IgE (RAST)



                    Denning DW et al, Clin Infect Dis 2003; 37:S265
Chronic cavitary pulmonary aspergillosis
                 (CCPA)




                              Patient RW
Patient RW                    September 1992
December 1991                 Relapse in normal lung
Pre surgical resection

                          www.aspergillus.man.ac.uk
Chronic cavitary pulmonary aspergillosis




                                                     Patient RW
                                                     July 1993




                         www.aspergillus.man.ac.uk
Chronic Cavitary Pulmonary Aspergillosis




                                      Patient JA
                                       Jan 2001
Chronic Cavitary Pulmonary Aspergillosis




                                       Patient JA
                                        Feb 2002
Chronic Cavitary Pulmonary Aspergillosis




                                       Patient JA
                                       April 2003
Chronic Cavitary Pulmonary Aspergillosis




                                       Patient JA
                                       July 2003
Chronic cavitary pulmonary aspergillosis




                                                         Patient JP
                                                         June 1999



              Denning DW et al, Clin Infect Dis 2003; 37:S265
Chronic Cavitary Pulmonary Aspergillosis, with
                 aspergilloma




                                                                 Patient JP
                                                                  July 2001


               Denning DW et al, Clin Infect Dis 2003; 37:S265
Chronic Fibrosing Pulmonary Aspergillosis




                                                          Patient JP
                                                          April 2002



                Denning DW et al, Clin Infect Dis 2003; 37:S265
Mannose Binding Lectin (MBL)- a key part
of the innate immune system
                         Di b
                         il dn
                         sh o
                          u ed
                          p
                             I ri w
                             nt i
                              tc t
                              eo h
                               an
                             cc e o
                             oi c r
                             l tr p
                              l n t
                              e e

    E
    x
    on
     1
                                        I ri w
                                        nt i
                                         tc t
                                         eo h
                                          an
                                          MA
                                           SP


    E
    x
    on
     2


                                                        C
                                                        R
                                                        D

    E
    x
    on
     3                                        2n t
                                              + ne
                                              C di
                                              aii s
                                               bg
    E
    x
    on
     4



                         Crosdale et al J Infect Dis 2001;184:653
Mannose Binding Protein
                    Mutations
5 mutations described
  2 in promoter region (less important)
  3 in open reading frame (M52, M54, M57)

Codon 54 mutation present in 16% of Caucasian
  homozygous in 2%

Defects associated with bacterial infections in
  children and hepatitis B carriage


                    Eisen & Minchinton Clin Infect Dis 2003;37:1496
CCPA and human gene defects

• 8 of 11 (72%) had low MBL genotypes p=<0.05
 (compared to normal controls)

• 8 of 17 (47%) had low MBL genotypes p=0.0002

• 32% and 21.5% frequency of 2 SPA2 mutations,
  compared with normals (18% and 11%) (p=0.021
  and p=0.044)

• not related to coeliac disease (<1 in 30)


            Crosdale et al J Infect Dis 2001;184:653; Vaid et al, unpublished.
CLASSIFICATION OF ASPERGILLOSIS
                    Invasive aspergillosis
                    • Acute (<1 month course)
Airways/nasal       • Subacute/chronic necrotising (1-3 months)
exposure to
airborne            Chronic aspergillosis (>3 months)
Aspergillus
                    • Chronic cavitary pulmonary
                    • Aspergilloma of lung
                    • Chronic fibrosing pulmonary
                    • Chronic invasive sinusitis
Persistence         • Maxillary (sinus) aspergilloma
without disease
- colonisation of
the airways or      Allergic
nose/sinuses        • Allergic bronchopulmonary (ABPA)
                    • Extrinsic allergic (broncho)alveolitis (EAA)
                    • Asthma with fungal sensitisation
                    • Allergic Aspergillus sinusitis (eosinophilic
                             fungal rhinosinusitis)
ALLERGIC BRONCHOPULMONARY
    ASPERGILLOSIS – Key diagnostic criteria
                                                           ABPA possible
•   Asthma
                                                           ABPA possible
•   Blood eosinophilia (>1,000 / cu mm)
                                                           ABPA probable
•   History of pulmonary infiltrates
                                                         ABPA almost certain
•   Central bronchiectasis


•   Precipitins against A. fumigatus positive                       If 3 tests +ve,
•   Aspergillus IgE antibody >2x asthma control                     then ABPA very
•   Aspergillus IgG antibody >2x asthma control                     likely,
                                                                    If all 4 +ve the
•   Total serum IgE concentration, >1000 iu/mL                      diagnosis
                                                                    established



    Rickett et al. Arch Intern Med 1983; 143: 1553; Patterson, Chest 2000;118:7
ABPA

                             After bronchoscopy




Before bronchoscopy




                             www.aspergillus.man.ac.uk
ABPA mucous plugging




             www.aspergillus.man.ac.uk
ABPA - CT showing central bronchiectasis




                        www.aspergillus.man.ac.uk
ABPA and surfactant




5 surfactant proteins in man, SPA1, SPA2, SPB, SPC and SPD
– all ‘collectin’ family


                       Mason et al, Am J Physiol 1998;275:L1-13.
ABPA – surfactant defects




2 exonic polymorphisms, and 2 intronic polymorphisms in SP-
A2 associated with ABPA

A1660G = OR of 4.78; or if combined with G1649C = OR 10.4

Also associated with higher peripheral eosinophilia


                Saxena et al, J Allergy Clin Immunol 2003;111:1001-7.
Eosinophilic fungal rhinosinusitis
            or allergic fungal sinusitis




Patient with chronic symptoms
of nasal obstruction, loss of smell
and nasal polyps
        Ponikau et al, Mayo Clinic Proc 1999;74:877 & WWW.aspergillus.man.ac.uk
Eosinophilic fungal rhinosinusitis
(link with airborne fungi - ?which most important




       = Myelin basic protein, highly toxic to local epithelium


                           Ponikau et al, Mayo Clinic Proc 1999;74:877
A link between Aspergillus and asthma?
Fungal-associated asthma – evidence

                      Severe asthma linked
                           with fungal
                          sensitisation

                                             Frequency of fungal
                                                sensitisation




   ABPA                Fungal-associated
                           asthma



  Treatment of ABPA                             High spore counts and
     and pilot data                               asthmatic attacks
Spore counts and asthma attacks and
 admission to hospital
     All circumstantial evidence
     •    Thunderstorm asthma – linked to Alternaria
     •    Asthma deaths (Chicago) linked to high
          ambient spores counts and season (summer
          autumn) when spore counts highest
     •    Asthma hospital admission linked to high
          ambient spore counts (Derby, New Orleans,
          Ottawa
     •    Asthma hospital attendance linked to high
          spore counts , but not pollen counts (Canada)
     •    Asthma symptoms increased on days of high
          spore counts (California, Pennsylvania)
O'Hollaren, N Engl J Med 1991; 324: 359; Newson, Occup Environ Med 2000; 57: 786-92.
Fungus at home
Environmental data
•   Mouldy housing associated with worse
    asthma, with a correlation between asthma
    severity and degree of dampness in the
    home and separately with visible mould
    growth
•   In Germany bronchial reactivity in children
    was associated with damp housing
•   Mouldy and damp school associated with
    asthma symptoms and emergency room visits
•   Highest concentration of Aspergillus
    fumigatus is at home

     Williamson, Thorax 1997;52:229. Taskinen, Acta Paediatr 1999; 88:1373.
Mild asthma – 564 (50%)
                           Moderate asthma – 333 (29%)
Severe asthma and moulds
                           Severe asthma – 235 (21%) – linked with
                           fungus skin test positivity




                       Zureik et al, Br Med J 2002;325:411
Asthma severity, house dust mites, cats
               and moulds
 Allergen    No asthma   Mild asthma     Moderate          Severe
               n= 111    FEV1 >75%     asthma FEV1      asthma FEV1
                            <90%        >60% <75%           >60%
                            n= 67         n= 42             n= 42

House dust     61%           71%          45%                77%
   mite
  Cats*        49%           51%          38%                35%


 Moulds#       17%           19%          36%                31%

                         * P = 0.05
                         # p = 0.01
                                         Langley, ATS 2004

Powerpoint on aspergillosis

  • 1.
    The extraordinary spectrumof diseases caused by Aspergillus David W. Denning Wythenshawe Hospital University of Manchester
  • 2.
    The genus Aspergillus- importance to humanity on the negative side: cause invasive and allergic disease in humans and other animals: A. fumigatus cause plant and food spoilage and produce mycotoxins: A. flavus and A. parasiticus www.aspergillus.man.ac.uk
  • 3.
    The genus Aspergillus- importance to humanity on the positive side: composting well-established model organism in cell biology and genetics: A. nidulans food production: enzymes and organic acids: A. niger East Asian foods: A. oryzae and A. sojae pharmaceuticals: echinocandins: A. nidulans and A. sydowi lovastatin: A. terreus fumagillin: A. fumigatus www.aspergillus.man.ac.uk
  • 4.
    Aspergillus Life-cycle Spores inhaled Germination Mass of hyphae Hyphal elongation (plateau phase) and branching www.aspergillus.man.ac.uk
  • 5.
    The genus Aspergillus– ~180 species, 38 have caused disease (able to grow at 37C) Common in the environment Aspergillus A. nidulans – may be amphotericin B resistant fumigatus conidial head A. niger A. flavus -sometimes to AmB of azole resistance A. fumigatus low frequency A. terreus – resistant amphotericin B resistant www.aspergillus.man.ac.uk
  • 6.
    CLASSIFICATION OF ASPERGILLOSIS Invasive aspergillosis • Acute (<1 month course) Airways/nasal • Subacute/chronic necrotising (1-3 months) exposure to airborne Chronic aspergillosis (>3 months) Aspergillus • Chronic cavitary pulmonary • Aspergilloma of lung • Chronic fibrosing pulmonary • Chronic invasive sinusitis Persistence • Maxillary (sinus) aspergilloma without disease - colonisation of the airways or Allergic nose/sinuses • Allergic bronchopulmonary (ABPA) • Extrinsic allergic (broncho)alveolitis (EAA) • Asthma with fungal sensitisation • Allergic Aspergillus sinusitis (eosinophilic fungal rhinosinusitis)
  • 7.
    Immunosuppression and infection •Inhalation of aspergillus spores is a common daily occurrence. A healthy immune system would normally remove the spores and no symptoms or infection would occur. • In individuals whose immune system may be suppressed either because of illness eg AIDS, cancer patients or drugs, spores may germinate and resulting tissue or systemic aspergillus invasion can result. • Individuals with allergies such as asthma, can also be vulnerable to aspergillus disease.
  • 8.
    Interaction of Aspergilluswith the host A unique microbial-host interaction Frequency of aspergillosis Frequency of aspergillosis Acute IA ABPA Allergic sinusitis Subacute IA Tracheobronchitis Aspergilloma Chronic cavitary Chronic fibrosing Immune dysfunction Normal Immune hyperactivity immune function . www.aspergillus.man.ac.uk
  • 9.
    Changing incidence offatal invasive mycoses in non-HIV patients in USA 0.8 Rate per 100,000 population 0.2 0.4 0.6 Candidiasis Aspergillosis 0.0 1981 1986 1991 1996 McNeil et al, Clin Infect Dis 2001;33:641
  • 10.
    Invasive pulmonary aspergillosis IPA Normal lung IPA occurs in ~7% of acute leukaemia patients, 10-15% allogeneic BMT patients www.aspergillus.man.ac.uk
  • 11.
    Unequivocal ‘Halo sign’surrounding a nodule Halo sign Herbrecht, Denning et al, NEJM 2002;347:408-15.
  • 12.
    Recent examples ofthe frequency of invasive aspergillosis Underlying condition Incidence Reference/year Acute myeloid leukaemia 8% Cornet, 2002 Acute lymphatic leukaemia 6.3% Cornet, 2002 Allogeneic HSCT 11-15% Grow, 2002; Marr, 2002 Lung transplantation 6.2-12.8% Minari, 2002; Singh,2003 Heart-lung transplantation 11% Duchini, 2002 Small bowel tranplantation 11% Duchini, 2002 AIDS 2.9% Libanore, 2002
  • 13.
    Bleeding as anaspect of disseminated invasive aspergillosis Fumagillin is anti-angiogenic A haemolysin described from Aspergillus fumigatus Other factors that contribute to thrombosis or a coagulopathy? Gillies & Campbell, www.aspergillus.man.ac.uk
  • 14.
    How does Aspergillusfumigatus cause thrombosis (clotting of vessels) and also bleeding? Interaction of conidia and endothelial cell Internalisation of projections conidia (and hyphae) by endothelial cells with injury apparent at 4 hours Filler et al, Blood 2004;103:2134; Paris et al, Infect Immun 1997;65:1510.
  • 15.
    Cerebral aspergillosis (abscess)in chronic lymphocytic leukaemia Dissemination via the blood stream to the brain occurs in ~5% of cases of invasive aspergillosis, and in ~40% of allogeneic bone marrow (HSCT) recipients www.aspergillus.man.ac.uk
  • 16.
    Early diagnosis ofinvasive aspergillosis is important Treatment started <10d >11d Mortality 40% 90% Von Eiff et al, Respiration 1995;62:241-7.
  • 17.
    Sputum Cultures forFungus Bacteriological media inferior to fungal media – 32% higher yield on fungal media A four day A. fumigatus culture on malt extract agar (above). Light microscopy pictures are taken at 1000x, stained with lacto-phenol cotton blue.
  • 18.
    Aspergillus Antigen Test •Diagnosis or surveillance? • Only blood, or BAL, CSF etc • Best OD cut-off - 0.7 • False positives in kids / antibiotics • False negative with antifungal prophylaxis • Not as useful for non-hematology • Not useful if pre-existing antibody Herbrecht et al, J Clin Microbiol 2002;20:1898-906; and others
  • 19.
    Outcome from invasiveaspergillosis – amphotericin B therapy Survival Functions by Site of Infection 1.0 .9 .8 Sinusitis (n =17) .7 .6 Multi-site (n =11) .5 Aspe rgilloma (n =10) .4 .3 .2 Pu lmonary (n =83) .1 CNS o r Dissemin ated (n =35) 0.0 0 30 60 90 120 150 180 210 240 270 300 330 360 Days Lin et al, Clin Infect Dis 2001;32:358
  • 20.
    Sub-acute invasive aspergillosisin AIDS www.aspergillus.man.ac.uk
  • 21.
    Sub-acute invasive aspergillosis • Less immunocompromised patients • Slower progression of disease (> 1 month) • Cavitary or nodular pulmonary disease typical • Vascular invasion less common • Dissemination less common • Antigen testing less useful • Antibody testing may be helpful in diagnosis www.aspergillus.man.ac.uk
  • 22.
    Chronic necrotizing aspergillosis (CNPA) Chronic necrotizing pulmonary aspergillosis (CNPA) is a subacute process usually found in patients with some degree of immunosuppression. Usually it is associated with underlying lung disease, alcoholism, or chronic corticosteroid therapy. Because it is uncommon, CNPA often remains unrecognized for weeks or months and causes a progressive cavitary pulmonary infiltrate.
  • 23.
    Chronic necrotising pulmonaryaspergillosis Right upper lobe showing circular Right lobe shows huge cavity shadow partly filled by a mass. PT MS containing some debris, with 1996 +ve aspergillus precipitins.Pt MS 1999 Right upper lobe. Patient has Same lobe shows expansion of diabetes and pulmonary the shadow, still partially filled mycobacterium avium- shows small with a mass. Pt MS 1998 cavitary lesion PT MS 1995. Denning, Clin Microbiol Infect 2001;7(Suppl 2):25-31.
  • 24.
    CLASSIFICATION OF ASPERGILLOSIS Invasive aspergillosis • Acute (<1 month course) Airways/nasal • Subacute/chronic necrotising (1-3 months) exposure to airborne Chronic aspergillosis (>3 months) Aspergillus • Chronic cavitary pulmonary • Aspergilloma of lung • Chronic fibrosing pulmonary • Chronic invasive sinusitis Persistence • Maxillary (sinus) aspergilloma without disease - colonisation of the airways or Allergic nose/sinuses • Allergic bronchopulmonary (ABPA) • Extrinsic allergic (broncho)alveolitis (EAA) • Asthma with fungal sensitisation • Allergic Aspergillus sinusitis (eosinophilic fungal rhinosinusitis)
  • 25.
    Aspergillus and airways Typesof aspergillosis of the airways • Colonisation (no disease – could be at risk) • Obstructing Aspergillus tracheobronchitis /Mucus impaction (non-invasive) • Aspergillus bronchitis/tracheobronchitis (superficially invasive only) • Ulcerative Aspergillus tracheobroncitis (locally invasive) (lung transplants – at anastomosis) • Pseudomembranous Aspergillus tracheobronchitis (Extensive disease, locally invasive, associated with IPA and may disseminate) Langley, ATS 2004
  • 26.
    Aspergillus tracheobronchitis Autopsy drawingof a ‘normal’ 3 year old who died over 10 days Wheaton, Path Trans 1890; 41:34-37
  • 27.
    Aspergillus tracheobronchitis Review of58 patients in literature for normal and immuno compromised patients - risk factors % None (ie normal) 25 Heart / Lung transplant 18 Solid tumour 15 BMT 13 Leukaemia 13 HIV/AIDS 8 Other 8 Kemper et al, Clin Infect Dis 1993; 17: 344
  • 28.
    Aspergilloma Fungus ball Patient RT December 2002
  • 29.
    Chronic pulmonary aspergillosis– pre-existing disease All 18 patients had prior pulmonary disease 9 TB, 5 with atypical mycobacteria 13 smokers or ex-smokers All 18 non-immunocompromised 3 excess alcohol Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 30.
    Chronic pulmonary aspergillosis- presentation Weight loss 16 / 18 (89%) Cough 15 / 18 (83%) Shortness of breath 9 / 18 (50%) Haemoptysis 9 / 18 (50%) Fatigue / malaise 5 / 18 (28%) Chest pain 3 / 18 (17%) Sputum production ++ 3 / 18 (17%) Fever 2 / 18 (11%) Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 31.
    Chronic pulmonary aspergillosis- serology All 18 patients had positive Aspergillus precipitins (1+ - 4+) All 18 patients had elevated inflammatory markers, CRP, PV and / or ESR 14 of 18 (78%) had elevated total IgE (>20), 13 >200 and 7 >400 9 of 14 (67%) had Aspergillus specific IgE (RAST) Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 32.
    Chronic cavitary pulmonaryaspergillosis (CCPA) Patient RW Patient RW September 1992 December 1991 Relapse in normal lung Pre surgical resection www.aspergillus.man.ac.uk
  • 33.
    Chronic cavitary pulmonaryaspergillosis Patient RW July 1993 www.aspergillus.man.ac.uk
  • 34.
    Chronic Cavitary PulmonaryAspergillosis Patient JA Jan 2001
  • 35.
    Chronic Cavitary PulmonaryAspergillosis Patient JA Feb 2002
  • 36.
    Chronic Cavitary PulmonaryAspergillosis Patient JA April 2003
  • 37.
    Chronic Cavitary PulmonaryAspergillosis Patient JA July 2003
  • 38.
    Chronic cavitary pulmonaryaspergillosis Patient JP June 1999 Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 39.
    Chronic Cavitary PulmonaryAspergillosis, with aspergilloma Patient JP July 2001 Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 40.
    Chronic Fibrosing PulmonaryAspergillosis Patient JP April 2002 Denning DW et al, Clin Infect Dis 2003; 37:S265
  • 41.
    Mannose Binding Lectin(MBL)- a key part of the innate immune system Di b il dn sh o u ed p I ri w nt i tc t eo h an cc e o oi c r l tr p l n t e e E x on 1 I ri w nt i tc t eo h an MA SP E x on 2 C R D E x on 3 2n t + ne C di aii s bg E x on 4 Crosdale et al J Infect Dis 2001;184:653
  • 42.
    Mannose Binding Protein Mutations 5 mutations described 2 in promoter region (less important) 3 in open reading frame (M52, M54, M57) Codon 54 mutation present in 16% of Caucasian homozygous in 2% Defects associated with bacterial infections in children and hepatitis B carriage Eisen & Minchinton Clin Infect Dis 2003;37:1496
  • 43.
    CCPA and humangene defects • 8 of 11 (72%) had low MBL genotypes p=<0.05 (compared to normal controls) • 8 of 17 (47%) had low MBL genotypes p=0.0002 • 32% and 21.5% frequency of 2 SPA2 mutations, compared with normals (18% and 11%) (p=0.021 and p=0.044) • not related to coeliac disease (<1 in 30) Crosdale et al J Infect Dis 2001;184:653; Vaid et al, unpublished.
  • 44.
    CLASSIFICATION OF ASPERGILLOSIS Invasive aspergillosis • Acute (<1 month course) Airways/nasal • Subacute/chronic necrotising (1-3 months) exposure to airborne Chronic aspergillosis (>3 months) Aspergillus • Chronic cavitary pulmonary • Aspergilloma of lung • Chronic fibrosing pulmonary • Chronic invasive sinusitis Persistence • Maxillary (sinus) aspergilloma without disease - colonisation of the airways or Allergic nose/sinuses • Allergic bronchopulmonary (ABPA) • Extrinsic allergic (broncho)alveolitis (EAA) • Asthma with fungal sensitisation • Allergic Aspergillus sinusitis (eosinophilic fungal rhinosinusitis)
  • 45.
    ALLERGIC BRONCHOPULMONARY ASPERGILLOSIS – Key diagnostic criteria ABPA possible • Asthma ABPA possible • Blood eosinophilia (>1,000 / cu mm) ABPA probable • History of pulmonary infiltrates ABPA almost certain • Central bronchiectasis • Precipitins against A. fumigatus positive If 3 tests +ve, • Aspergillus IgE antibody >2x asthma control then ABPA very • Aspergillus IgG antibody >2x asthma control likely, If all 4 +ve the • Total serum IgE concentration, >1000 iu/mL diagnosis established Rickett et al. Arch Intern Med 1983; 143: 1553; Patterson, Chest 2000;118:7
  • 46.
    ABPA After bronchoscopy Before bronchoscopy www.aspergillus.man.ac.uk
  • 47.
    ABPA mucous plugging www.aspergillus.man.ac.uk
  • 48.
    ABPA - CTshowing central bronchiectasis www.aspergillus.man.ac.uk
  • 49.
    ABPA and surfactant 5surfactant proteins in man, SPA1, SPA2, SPB, SPC and SPD – all ‘collectin’ family Mason et al, Am J Physiol 1998;275:L1-13.
  • 50.
    ABPA – surfactantdefects 2 exonic polymorphisms, and 2 intronic polymorphisms in SP- A2 associated with ABPA A1660G = OR of 4.78; or if combined with G1649C = OR 10.4 Also associated with higher peripheral eosinophilia Saxena et al, J Allergy Clin Immunol 2003;111:1001-7.
  • 51.
    Eosinophilic fungal rhinosinusitis or allergic fungal sinusitis Patient with chronic symptoms of nasal obstruction, loss of smell and nasal polyps Ponikau et al, Mayo Clinic Proc 1999;74:877 & WWW.aspergillus.man.ac.uk
  • 52.
    Eosinophilic fungal rhinosinusitis (linkwith airborne fungi - ?which most important = Myelin basic protein, highly toxic to local epithelium Ponikau et al, Mayo Clinic Proc 1999;74:877
  • 53.
    A link betweenAspergillus and asthma?
  • 54.
    Fungal-associated asthma –evidence Severe asthma linked with fungal sensitisation Frequency of fungal sensitisation ABPA Fungal-associated asthma Treatment of ABPA High spore counts and and pilot data asthmatic attacks
  • 55.
    Spore counts andasthma attacks and admission to hospital All circumstantial evidence • Thunderstorm asthma – linked to Alternaria • Asthma deaths (Chicago) linked to high ambient spores counts and season (summer autumn) when spore counts highest • Asthma hospital admission linked to high ambient spore counts (Derby, New Orleans, Ottawa • Asthma hospital attendance linked to high spore counts , but not pollen counts (Canada) • Asthma symptoms increased on days of high spore counts (California, Pennsylvania) O'Hollaren, N Engl J Med 1991; 324: 359; Newson, Occup Environ Med 2000; 57: 786-92.
  • 56.
    Fungus at home Environmentaldata • Mouldy housing associated with worse asthma, with a correlation between asthma severity and degree of dampness in the home and separately with visible mould growth • In Germany bronchial reactivity in children was associated with damp housing • Mouldy and damp school associated with asthma symptoms and emergency room visits • Highest concentration of Aspergillus fumigatus is at home Williamson, Thorax 1997;52:229. Taskinen, Acta Paediatr 1999; 88:1373.
  • 57.
    Mild asthma –564 (50%) Moderate asthma – 333 (29%) Severe asthma and moulds Severe asthma – 235 (21%) – linked with fungus skin test positivity Zureik et al, Br Med J 2002;325:411
  • 58.
    Asthma severity, housedust mites, cats and moulds Allergen No asthma Mild asthma Moderate Severe n= 111 FEV1 >75% asthma FEV1 asthma FEV1 <90% >60% <75% >60% n= 67 n= 42 n= 42 House dust 61% 71% 45% 77% mite Cats* 49% 51% 38% 35% Moulds# 17% 19% 36% 31% * P = 0.05 # p = 0.01 Langley, ATS 2004